



# SUNSHINE HOLDINGS PLC

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE QUARTER ENDED  
31ST DECEMBER 2023

## GROUP CHIEF EXECUTIVE OFFICER'S MESSAGE

### Dear Shareholder,

The Group recorded a consolidated revenue of LKR 42.4 billion for the 9-months ended 31st December 2023 (9MFY24), up 9.9% YoY. The Group revenue, from Healthcare, Consumer and Agribusiness sectors, contributed 49.6%, 35.0% and 15.3% respectively.

In 9MFY24 the gross profit improved to LKR 13.6 billion, up 33.6% YoY, driven by both revenue growth and 569 bps increase in margins. The Group EBIT closed at LKR 7.4 billion, an increase of 27.0% YoY. Group PAT was LKR 5.5 billion in 9MFY24 compared to LKR 3.8 billion reported during the same period last year. The net finance cost for the period amounted to LKR 283 million (includes interest on lease liabilities of LKR 98 million and net exchange loss of LKR 146 million) compared to LKR 627 million during the last year. The contraction in finance cost for the period is owing to lower interest rates and favorable impact from exchange rate movements.

Profit attributable to equity shareholders (PATMI) closed at LKR 4.0 billion for 9MFY24, an increase of 80% YoY.

### Financial Snapshot

	3QFY24	Vs 3QFY23	Vs 2QFY24
Healthcare	7,197	19.4%	-4.4%
Consumer	5,136	-7.0%	2.7%
Agri	1,885	-8.9%	-15.9%
Other	11	0.0%	-47.6%
<b>Revenue</b>	<b>14,229</b>	<b>4.4%</b>	<b>-3.8%</b>
Gross Profit	4,793	67.9%	-1.3%
GP Margin	33.7%	12.7%	0.8%
<b>EBIT</b>	<b>2,568</b>	<b>72.2%</b>	<b>-8.6%</b>
EBIT Margin	18.0%	7.1%	-1.0%
Net Finance Cost	(121)	-68.8%	764.3%
Income Tax Expense	(635)	84.1%	7.8%
<b>PAT</b>	<b>1,812</b>	<b>188.5%</b>	<b>-17.9%</b>

### Healthcare

Healthcare revenue for 9MFY24 grew 19.3% YoY, due to the increased topline of all business units within the sector.

Improvement in EBIT Margin in the Healthcare sector is owing to the higher contribution of medical devices and pharmaceutical manufacturing business driven by price and volume growth. However, the impact was partially offset by the margin contraction in the pharmaceutical agency business.

In the Pharma segment, revenue growth of 4.4% YoY is primarily driven by volume growth, despite challenges in profitability due to LKR depreciation and price controls. Medical devices segment grew 40.8% YoY driven by both price and volume increase.

Revenue of Healthguard Pharmacy saw a 20.2% YoY increase, fueled by an improved bill count which grew 19.0% compared to the same period last year and a gross margin improvement driven by the favorable topline impact of the business.

Lina pharma manufacturing business, experienced revenue growth of 193.6% YoY, driven by higher volumes in the Metered Dose Inhaler (MDI) plant, which is now fully operational.

### Consumer

The Consumer sector, which includes both export and domestic business, reported revenue of LKR 14.8 billion in 9MFY24, with an increase of 5.3% YoY.

The Export business faced significant challenges due to contraction is revenue by 28.0% YoY owing to the reduction in volume of 4.1% YoY during the period.

The Domestic consumer business had an impressive performance for 9MFY24, driven by increased volumes in the tea segment, despite a volume contraction in confectionary, resulting in a revenue growth of 31.5% in 9MFY24.

Our Consumer brands Zesta, Watawala, Ran Kahata and Daintee continued to grow market shares.

The tea category experienced a volume growth of 10.0% YoY in 9MFY24 and a value growth of 58.8% YoY. The confectionery segment revenue contracted by 20.9% YoY, despite an increase in selling price, and a volume contraction of 27.0% YoY. The tea category experienced a volume growth of 10.0% YoY in 9MFY24 and a value growth of 58.8% YoY. The confectionery segment revenue contracted by 20.9% YoY, despite an increase in selling price, and a volume contraction of 27.0% YoY.

EBIT margin improved in 9MFY24 to 12.0%, against 6.4% last year driven by the topline impact from the local tea business.

PAT from the Consumer sector increased by 111.6% YoY due to the growth in local business, which was partially offset by the adverse impact from the export business.

### Agribusiness

The Agri sector recorded LKR 6.5 billion in 9MFY24 in revenue, a 2.5% decline from same period last year mainly driven by the decline in revenue of palm oil business (down 6.0% YoY). The top line of the segment was impacted by the downward trend in palm oil prices. Palm oil production increased by 16.7% YoY to 12.2 million Kgs in the current period compared to 10.5 million Kgs in the same period last

year. PAT for the period amounted to LKR 2.2 billion, a decrease of 15.1% YoY. The PAT margin deteriorated mainly due to the drop in palm oil price, and due to the imposition of the Special Commodity Levy and higher tax rate.

The Dairy business revenue grew by 23.0% YoY due to increases in both sales volume and milk price. The dairy segment recorded a net profit of LKR 2.5 million during 9MFY24 compared to net loss of LKR 63.5 million in 9MFY23 primarily due to the improved topline. The farm had an average herd strength of 1,795 of which 819 were milking cows in 9MFY24.

### Outlook

In Healthcare we are closely monitoring the changes in the exchange rate, which is sensitive to our margins. With tighter fiscal measures, consumer spending power is going to be the key challenge over the next few quarters. Compression of margin is probably expected due to depreciation of the Rupee since the MRP's for key molecules were reduced by 16% in June 2023.

The Consumer sector will continue to face challenges owing to macroeconomic pressures on consumer purchasing power. However, the negative impact on the sector is expected to be offset by the recently acquired export business, which we expect to achieve further growth and will be a key focus area for the Group.

With tea auction prices easing from their peak, we aim to drive volume growth, especially in the export business. In the domestic market, we will continue to invest behind our brands selectively to maintain our high market shares. We will continue to drive distribution synergies in the retail channels.

We expect palm oil prices to remain stable in the near term, in line with global pricing, while crop volumes are expected to increase due to the increase in yield from the maturity of young fields. Meanwhile, milk yield is expected to remain healthy and a decrease in feed cost is expected in the coming quarters due to the better management of feed in past months.

As I commence my tenure as Group Chief Executive Officer of Sunshine Holdings PLC, I want to express my gratitude to the Board for placing their trust in me to lead this group and nurture the dynamic team of leaders that the company has across all levels and sectors. I wish to place on record my deep appreciation for my predecessor Vish Govindasamy who has led this group for over 15 years during which time the business has grown tremendously in value and hands me a solid foundation upon which to build the future. As Deputy Chairman he will continue to provide wise counsel to me and the team.

Further details of the Group's performance are available on the company website. (<https://www.sunshineholdings.lk/investor/financial-reports>)



**Shyam Sathasivam**  
Group Chief Executive Officer  
13th February 2024  
Colombo

## CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - GROUP

	Unaudited			Unaudited			Audited
	Period ended	Period ended	Change	Quarter ended	Quarter ended	Change	Year ended
	31st December 2023	31st December 2022		31st December 2023	31st December 2022		31st March 2023
<b>Continuing operations</b>							
Revenue	42,385,719	38,561,396	10	14,228,515	13,633,508	4	51,886,754
Cost of sales	(28,775,631)	(28,375,348)	1	(9,435,183)	(10,778,412)	(12)	(38,380,521)
<b>Gross profit</b>	<b>13,610,088</b>	<b>10,186,048</b>	<b>34</b>	<b>4,793,332</b>	<b>2,855,096</b>	<b>68</b>	<b>13,506,233</b>
Other income	306,798	190,736	61	101,455	23,276	336	154,821
Selling & distribution expenses	(3,835,398)	(2,403,863)	60	(1,439,987)	(721,754)	100	(3,381,440)
Administration expenses	(2,687,774)	(2,151,000)	25	(886,610)	(665,919)	33	(3,278,685)
<b>Results from operating activities</b>	<b>7,393,714</b>	<b>5,821,921</b>	<b>27</b>	<b>2,568,190</b>	<b>1,490,700</b>	<b>72</b>	<b>7,000,929</b>
Finance income	576,648	593,162	(3)	72,803	125,948	(42)	477,806
Finance cost	(859,692)	(1,219,981)	(30)	(194,381)	(513,455)	(62)	(1,463,801)
<b>Net finance cost</b>	<b>(283,044)</b>	<b>(626,819)</b>	<b>(55)</b>	<b>(121,578)</b>	<b>(387,507)</b>	<b>(69)</b>	<b>(985,995)</b>
Impairment of Goodwill	-	(210,000)	-	-	(130,000)	-	(354,295)
<b>Profit before tax</b>	<b>7,110,670</b>	<b>4,985,102</b>	<b>43</b>	<b>2,446,612</b>	<b>973,192</b>	<b>151</b>	<b>5,660,639</b>
Income tax expense	(1,661,576)	(1,206,462)	38	(634,158)	(345,314)	84	(2,043,787)
<b>Profit for the period</b>	<b>5,449,094</b>	<b>3,778,640</b>	<b>44</b>	<b>1,812,454</b>	<b>627,878</b>	<b>189</b>	<b>3,616,852</b>
Profit or (loss) on discontinued operations, net of tax	-	-	-	-	-	-	-
<b>Other comprehensive income</b>							
"Equity investments at FVOCI – net change in fair value"	-	-	-	-	-	-	(130,397)
Exchange gain/(Loss) on foreign operation translation	(1,125)	4,185	(127)	720	1,609	-	711
Related tax	-	-	-	-	-	-	84,626
Remeasurement of retirement benefit liability	-	-	-	-	-	-	(129,252)
Tax on other comprehensive income	-	-	-	-	-	-	-
<b>Total other comprehensive income for the period</b>	<b>(1,125)</b>	<b>4,185</b>	<b>(127)</b>	<b>720</b>	<b>1,609</b>	<b>-</b>	<b>(174,312)</b>
<b>Total comprehensive income for the period</b>	<b>5,447,969</b>	<b>3,782,825</b>	<b>44</b>	<b>1,813,174</b>	<b>629,486</b>	<b>188</b>	<b>3,442,540</b>
<b>Profit attributable to:</b>							
Owners of the parent company	3,962,844	2,207,050	80	1,399,631	272,182	414	2,263,930
Non-controlling interest	1,486,250	1,571,590	(5)	412,823	355,695	16	1,352,922
<b>Other comprehensive income attributable to:</b>							
Owners of the parent company	(1,125)	4,185	(127)	720	1,609	(55)	(123,719)
Non-controlling interest	-	-	-	-	-	-	(50,593)
<b>Total comprehensive income for the period</b>	<b>5,447,969</b>	<b>3,782,824</b>	<b>44</b>	<b>1,813,174</b>	<b>629,486</b>	<b>188</b>	<b>3,442,540</b>
Basic earnings per share	8.05	4.55		2.84	0.56		4.67

Figures in brackets indicate deductions.  
The above figures are not audited

## CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - COMPANY

	Unaudited			Unaudited	Unaudited		Audited
	Period ended 31st December 2023	Period ended 31st December 2022	Change	Quarter ended 31st December 2023	Quarter ended 31st December 2022	Change	Year ended 31st March 2023
Revenue	1,562,625	829,223	88	1,053,927	156,291	574	1,381,728
Cost of sales	-	-	n/m	-	-	n/m	-
<b>Gross profit</b>	<b>1,562,625</b>	<b>829,223</b>	<b>88</b>	<b>1,053,927</b>	<b>156,291</b>	<b>574</b>	<b>1,381,728</b>
Other income	359,813	355,329	1	149,419	128,241	17	472,625
Administration expenses	(475,485)	(468,532)	1	(172,851)	(160,635)	8	(697,726)
<b>Results from operating activities</b>	<b>1,446,953</b>	<b>716,020</b>	<b>102</b>	<b>1,030,495</b>	<b>123,897</b>	<b>732</b>	<b>1,156,627</b>
Finance income	118,816	85,180	39	23,335	33,832	(31)	122,206
Finance cost	(1,172)	(27,932)	(96)	(175)	(8,829)	(98)	(27,759)
<b>Net finance cost</b>	<b>117,644</b>	<b>57,248</b>	<b>106</b>	<b>23,160</b>	<b>25,003</b>	<b>(7)</b>	<b>94,447</b>
Profit before tax	1,564,597	773,268	102	1,053,655	148,900	608	1,251,074
Income tax expense	6,687	(40,035)	(117)	764	6,652	(89)	(738)
<b>Profit for the period</b>	<b>1,571,284</b>	<b>733,233</b>	<b>114</b>	<b>1,054,419</b>	<b>155,552</b>	<b>578</b>	<b>1,250,336</b>
<b>Other comprehensive income</b>							
Equity investments at FVOCI – net change	-	-	-	-	-	-	(130,397)
Relax Tax	-	-	-	-	-	-	46,928
Defined benefit plan actuarial gain/(loss)	-	-	-	-	-	-	1,482
<b>Total other comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(81,987)</b>
<b>Total comprehensive income for the period</b>	<b>1,571,284</b>	<b>733,233</b>	<b>114</b>	<b>1,054,419</b>	<b>155,552</b>	<b>578</b>	<b>1,168,349</b>
Basic earnings per share from continuing operations	3.19	1.51		2.14	0.32		2.58

Figures in brackets indicate deductions.  
n/m- not meaningful


## STATEMENT OF FINANCIAL POSITION - GROUP

	Unaudited	Audited
	As at 31st December 2023	As at 31st March 2023
	RS '000	RS '000
<b>ASSETS</b>		
<b>Non current assets</b>		
Property, plant and equipment	6,743,193	6,735,559
Intangible assets	303,608	349,108
Leasehold right to bare land	372,392	243,876
Biological assets	3,539,245	3,503,611
Investment property	631,212	627,528
Other investments	483,417	519,017
Deferred tax assets	340,681	320,099
Goodwill on Acquisition	1,387,106	1,387,106
<b>Total non-current assets</b>	<b>13,800,854</b>	<b>13,685,904</b>
<b>Current assets</b>		
Biological assets-growing crops on bearer plants	80,331	86,126
Inventories	11,939,608	9,861,121
Other investments	1,075,574	1,084,020
Current tax assets	138,688	139,070
Trade & other receivables	11,679,113	7,892,295
Amounts due from related parties	97,625	149,443
Cash & cash equivalent	3,733,529	3,110,102
<b>Total current assets</b>	<b>28,744,468</b>	<b>22,322,177</b>
<b>Total assets</b>	<b>42,545,322</b>	<b>36,008,081</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Stated capital	4,240,394	4,240,394
Reserves	190,677	191,803
Retained earnings	13,849,155	11,356,303
<b>Equity attributable to owners of the company</b>	<b>18,280,226</b>	<b>15,788,500</b>
Non-controlling interests	3,664,320	3,448,610
<b>Total equity</b>	<b>21,944,546</b>	<b>19,237,110</b>
<b>Non-current liabilities</b>		
Loans and borrowings	1,904,379	1,911,006
Employee benefits	870,339	883,412
Refundable Deposit Received	2,914	2,518
Deferred income and capital grants	37,316	39,084
Deferred tax	1,399,163	1,404,406
<b>Total current liabilities</b>	<b>4,214,111</b>	<b>4,240,426</b>
<b>Current liabilities</b>		
Trade and other payables	8,213,228	6,423,945
Amounts due to related parties	-	55,000
Current tax liabilities	894,830	555,160
Loans and borrowings	4,478,536	3,387,971
Bank overdraft	2,800,071	2,108,469
<b>Total current liabilities</b>	<b>16,386,665</b>	<b>12,530,545</b>
<b>Total equity and liabilities</b>	<b>42,545,322</b>	<b>36,008,081</b>
Net asset value per share (Rs.)	37.16	32.08

Figures in brackets indicate deductions.

The above figures are not audited


It is certified that the Financial Statements have been prepared in compliance with the requirements of the Companies Act No. 7 of 2007.




Group Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these financial statements.

Approved and signed for and on behalf of the Board,



Chairman  
February 13th, 2024  
Colombo



Deputy Chairman


**STATEMENT OF FINANCIAL POSITION - COMPANY**

	Unaudited	Audited
	As at 31st	As at 31st
	December 2023	March 2023
	RS '000	RS '000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	10,347	25,523
Intangible assets	15,807	19,759
Investment in subsidiaries	7,248,733	7,248,733
Other investments	438,369	465,734
Deferred tax assets	127,935	121,249
<b>Total non-current assets</b>	<b>7,841,191</b>	<b>7,880,998</b>
<b>Current assets</b>		
Inventories	735	1,883
Current tax assets	74,197	74,195
Trade & other receivables	59,599	28,133
Amounts due from related parties	278,063	233,869
Other Short Term Investments	821,838	225,000
Cash & cash equivalent	716,813	814,025
<b>Total current assets</b>	<b>1,951,245</b>	<b>1,377,105</b>
<b>Total assets</b>	<b>9,792,436</b>	<b>9,258,103</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Stated capital	4,240,394	4,240,394
Reserves	184,270	184,270
Retained earnings	5,151,775	4,638,236
Equity attributable to owners of the company	9,576,439	9,062,900
Non-controlling interests	-	-
<b>Total equity</b>	<b>9,576,439</b>	<b>9,062,900</b>
<b>Non-current liabilities</b>		
Loans and borrowings	-	3,470
Employee benefits	151,392	141,256
<b>Total non-current liabilities</b>	<b>151,392</b>	<b>144,726</b>
<b>Current liabilities</b>		
Trade and other payables	59,468	34,158
Amounts due to related parties	-	13
Current tax liabilities	-	-
Loans and borrowings	5,137	16,306
Bank overdraft	-	-
<b>Total current liabilities</b>	<b>64,605</b>	<b>50,477</b>
<b>Total equity and liabilities</b>	<b>9,792,436</b>	<b>9,258,103</b>
Net asset value per share (Rs.)	19.47	18.42

Figures in brackets indicate deductions.

The above figures are not audited


It is certified that the Financial Statements have been prepared in compliance with the requirements of the Companies Act No. 7 of 2007.



Group Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these financial statements.


Approved and signed for and on behalf of the Board,



Chairman

February 13th, 2024

Colombo



Deputy Chairman

**CONDENSED STATEMENT OF CHANGES IN EQUITY - GROUP**

FOR THE QUARTER ENDED 31ST DECEMBER 2023

In LKR '000	Attributable to owners of the company					Total	Non-controlling interest	Total equity
	Stated capital	Reserve on exchange gain or loss	General reserve	Fair value gain or loss reserve on AFS	Retained earnings			
<b>Adjusted Balance as at 01st April 2022</b>	<b>1,641,715</b>	<b>4,224</b>	<b>1,258</b>	<b>269,079</b>	<b>10,510,766</b>	<b>12,427,042</b>	<b>5,347,478</b>	<b>17,774,520</b>
<b>Total Comprehensive Income</b>								
Profit for nine months	-	-	-	-	2,207,049	2,207,049	1,571,590	3,778,639
Total other comprehensive income for nine months	-	-	-	-	4,185	4,185	-	4,185
<b>Total comprehensive income for nine months</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,211,233</b>	<b>2,211,233</b>	<b>1,571,590</b>	<b>3,782,824</b>
Acquisition of 2.59% of Watawala Plantation PLC shares	-	-	-	-	(291,034)	(291,034)	(170,747)	(461,781)
Acquisition of 28% in Sunshine Healthcare Lanka Limited	-	-	-	-	(736,115)	(736,115)	(1,862,564)	(2,598,679)
Share Issue to Akbar Brothers (Private) Limited	2,598,679	-	-	-	-	2,598,679	-	2,598,679
Capital Infusion in Watawala Dairy Ltd	-	-	-	-	(14,778)	(14,778)	14,778	-
Dividend to owners for 2021/22	-	-	-	-	(245,987)	(245,987)	(1,370,682)	(1,616,669)
	<b>2,598,679</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(1,287,914)</b>	<b>1,310,765</b>	<b>(3,389,214)</b>	<b>(2,078,449)</b>
<b>Balance as at 31st December 2022</b>	<b>4,240,394</b>	<b>4,224</b>	<b>1,258</b>	<b>269,079</b>	<b>11,434,085</b>	<b>15,949,041</b>	<b>3,529,854</b>	<b>19,478,894</b>
<b>Total Comprehensive Income</b>								
Profit for the three months	-	-	-	-	56,880	56,880	(218,669)	(161,788)
Total other comprehensive income for the three months	-	711	-	(83,469)	(45,146)	(127,904)	(50,593)	(178,497)
<b>Total comprehensive income for three months</b>	<b>-</b>	<b>711</b>	<b>-</b>	<b>(83,469)</b>	<b>11,735</b>	<b>(71,024)</b>	<b>(269,261)</b>	<b>(340,285)</b>
Acquisition of NCI	-	-	-	-	7,982	7,982	(7,982)	-
WHT payment on dividend distribution from Sunshine Healthcare Lanka Ltd	-	-	-	-	(97,500)	(97,500)	-	(97,500)
Transactions with NCI	-	-	-	-	-	-	196,000	196,000
	<b>-</b>	<b>711</b>	<b>-</b>	<b>(83,469)</b>	<b>(77,783)</b>	<b>(160,542)</b>	<b>(81,243)</b>	<b>(241,785)</b>
<b>Balance as at 31st March 2023</b>	<b>4,240,394</b>	<b>4,935</b>	<b>1,258</b>	<b>185,609</b>	<b>11,356,302</b>	<b>15,788,499</b>	<b>3,448,610</b>	<b>19,237,109</b>
<b>Total Comprehensive Income</b>								
Profit for nine months	-	-	-	-	3,962,844	3,962,844	1,486,250	5,449,094
Total other comprehensive income for nine months	-	(1,125)	-	-	-	(1,125)	-	(1,125)
<b>Total comprehensive income for nine months</b>	<b>-</b>	<b>(1,125)</b>	<b>-</b>	<b>-</b>	<b>3,962,844</b>	<b>3,961,719</b>	<b>1,486,250</b>	<b>5,447,968</b>
Dividend paid to owners for 2022/23	-	-	-	-	(565,770)	(565,770)	-	(565,770)
Dividend paid to owners for 2023/24	-	-	-	-	(491,974)	(491,974)	(1,365,201)	(1,857,175)
WHT payment on dividend distribution	-	-	-	-	(363,724)	(363,724)	(46,862)	(410,586)
Lina Manufacturing (Pvt) Ltd and Lina Spiro (Pvt) Ltd Share Swap	-	-	-	-	(48,523)	(48,523)	141,523	93,000
	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(1,469,991)</b>	<b>(1,469,991)</b>	<b>(1,270,540)</b>	<b>(2,740,531)</b>
<b>Balance as at 31st December 2023</b>	<b>4,240,394</b>	<b>3,810</b>	<b>1,258</b>	<b>185,609</b>	<b>13,849,155</b>	<b>18,280,227</b>	<b>3,664,320</b>	<b>21,944,546</b>

The above figures are not audited

**STATEMENT OF CHANGES IN EQUITY - COMPANY**

FOR THE QUARTER ENDED 31ST DECEMBER 2023

In LKR '000	Stated capital	Fair value gain or loss reserve on AFS	General reserve	Retained earnings	Total
<b>Adjusted Balance as at 01st April 2022</b>	<b>1,641,715</b>	<b>264,999</b>	<b>1,258</b>	<b>3,633,886</b>	<b>5,541,858</b>
<b>Total comprehensive income for the year</b>					
Profit for nine months	-	-	-	733,232	733,232
Total other comprehensive income for nine months	-	-	-	-	-
<b>Total comprehensive income for the year</b>		<b>-</b>		<b>733,232</b>	<b>733,232</b>
Issue of shares to Akbar Brothers (Private) Limited	2,598,679	-	-	-	2,598,679
Dividend to owners - 2021/22	-	-	-	(245,987)	(245,987)
<b>Balance as at 31st December 2022</b>	<b>4,240,394</b>	<b>264,999</b>	<b>1,258</b>	<b>4,121,132</b>	<b>8,627,782</b>
<b>Total comprehensive income for the period</b>					
Profit for the three months	-	-	-	517,104	517,104
Total other comprehensive income for the three months	-	(81,987)	-	-	(81,987)
<b>Total comprehensive income for the three months</b>	<b>4,240,394</b>	<b>183,012</b>	<b>1,258</b>	<b>4,638,235</b>	<b>9,062,899</b>
<b>Balance as at 31st March 2023</b>	<b>4,240,394</b>	<b>183,012</b>	<b>1,258</b>	<b>4,638,235</b>	<b>9,062,899</b>
<b>Total comprehensive income for the period</b>					
Profit for nine months	-	-	-	1,571,284	1,571,284
Total other comprehensive income for nine months	-	-	-	-	-
<b>Total comprehensive income for the nine months</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,571,284</b>	<b>1,571,284</b>
Dividend to owners - 2022/23 and 2023/24	-	-	-	(1,057,744)	(1,057,744)
<b>Balance as at 31st December 2023</b>	<b>4,240,394</b>	<b>183,012</b>	<b>1,258</b>	<b>5,151,775</b>	<b>9,576,439</b>

Figures in brackets indicate deductions.  
The above figures are not audited



**STATEMENT OF CASH FLOWS - GROUP**

	Unaudited Quarter ended 31st December 2023	Audited Year ended 31st March 2023
	RS '000	RS '000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
<b>Profit before income tax</b>	<b>7,110,670</b>	<b>5,660,638</b>
<b>Adjustments for;</b>		
Interest Income	(378,977)	(477,806)
Profit on Disposal of Property, Plant & Equipment	(9,078)	(25,722)
Write-off of Intangible assets	-	(458)
Biological assets-growing crops on bearer plants	-	(14,455)
Impairment of Goodwill	-	354,295
Fair value changes in livestock	7,845	157,440
Interest Expense	713,689	1,463,801
Depreciation of Property, Plant and Equipment	555,638	787,998
Amortization of Intangible Assets	63,514	87,055
Depreciation of mature plantations	133,599	196,741
Provision/(Reversal) for Bad and Doubtful Debts	256,711	175,819
Provision/ (Reversal) of impairment of inventories	(143,508)	154,756
Amortisation of Deferred Income	(1,769)	(2,358)
Amortization of Lesehold land right	8,362	100,932
Fair value gain/loss on investments	(6,973)	39,989
Provision for Gratuity excluding actuarial gain/loss	82,731	162,859
Rent Concession	-	(4,605)
Fair value gain/loss on Consumer Biological Assets	5,795	(10,486)
<b>Operating profit before working capital changes</b>	<b>8,398,250</b>	<b>8,806,433</b>
(Increase)/decrease in inventories	(1,934,979)	(2,262,768)
(Increase)/decrease in trade and other receivables	(4,043,529)	(1,053,650)
(Increase)/decrease in amounts due from related parties	51,817	(106,254)
Increase/(decrease) in trade and other payables	1,788,373	6,143
Increase/(decrease) in amounts due to related parties	(54,089)	(10,728)
<b>Cash generated from/ (used in) operations</b>	<b>4,205,843</b>	<b>5,379,176</b>
Interest paid	(511,211)	(1,362,250)
Income tax paid	(1,757,929)	(1,944,113)
Gratuity paid	(95,805)	(66,454)
<b>Net cash generated from / (used in) operating activities</b>	<b>1,840,898</b>	<b>2,006,359</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Interest Received	378,977	477,806
(Investments)/ Disposal in Other Investments	888,118	72,714
(Investments)/ Disposal in Short term Investments	(845,704)	(366,293)
(Investments)/ Disposal in gratuity fund	9,000	19,030
Additions to Bearer plants	(35,377)	(64,052)
Additions of live stock	(181,702)	(165,176)
Acquisition of PPE	(566,046)	(1,502,498)
Acquisition of Intangible Assets	(18,013)	(40,135)
Proceeds from Disposal of PPE	11,852	472,160
Proceeds from sales of livestock	40,002	57,870
Disposal of Shares held in Subsidiary	93,000	-
Acquisition of Noncontrolling interest in Subsidiaries	-	(461,781)
Acquisition of Subsidiaries (net of cash)	-	(1,563,684)
Acquisition of Investment property	(3,685)	(13,293)
<b>Net cash generated from / (used in) Investing activities</b>	<b>(229,578)</b>	<b>(3,077,332)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Receipts of Interest Bearing Borrowings	3,893,882	13,702,041
Proceeds from share Issued by subsidiaries to NCI	-	196,000
Repayments of Interest Bearing Borrowings	(3,089,736)	(12,467,823)
Payment to lease creditor	(59,571)	(88,865)
Dividend Paid	(2,422,945)	(1,616,668)
<b>Net cash from / (used in) financing activities</b>	<b>(1,678,370)</b>	<b>(275,315)</b>
Net increase/(decrease) in cash and cash equivalents	(67,050)	(1,346,288)
Cash and cash equivalents at the beginning of the period	1,001,633	2,347,210
Effect of exchange rate changes on cash and cash equivalents	(1,125)	711
<b>Cash and cash equivalents at the end of the period</b>	<b>933,458</b>	<b>1,001,633</b>
<b>Cash and cash equivalents</b>		
Cash in hand & bank	3,733,529	3,110,102
Bank overdraft	(2,800,071)	(2,108,469)
	<b>933,458</b>	<b>1,001,633</b>

Figures in brackets indicate deductions.  
The above figures are not audited

## STATEMENT OF CASH FLOWS - COMPANY

	Unaudited Quarter ended 31st December 2023 LKR	Audited Year ended 31st March 2023 LKR
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
<b>Profit before income tax</b>	<b>1,564,597</b>	<b>1,251,075</b>
<b>Adjustments for;</b>		
Interest income	(118,816)	(91,626)
Interest expense	1,173	28,973
Dividend income	-	-
Fair value gain/ loss in quoted shares and unit trust	(6,208)	355
Depreciation of Property, Plant and Equipment	20,918	25,050
Amortization of Intangible Assets	-	5,269
Provision for gratuity	10,136	29,603
<b>Operating profit before working capital changes</b>	<b>1,471,800</b>	<b>1,248,699</b>
(Increase)/decrease in trade and other receivables	(31,466)	108,596
(Increase)/Decrease in Inventory	1,148	(1,883)
(Increase)/decrease in amounts due from related parties	(44,194)	8,463
Increase/(decrease) in trade and other payables	25,310	(64,506)
Increase/(decrease) in amounts due to related parties	(12)	4
<b>Cash generated from/ (used in) operations</b>	<b>1,422,586</b>	<b>1,299,373</b>
Interest paid	(269)	(24,914)
Income tax paid	-	(103,702)
<b>Net cash generated from / (used in) operating activities</b>	<b>1,422,318</b>	<b>1,170,757</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Interest received	143,908	67,152
Acquisition of non-controlling interest in subsidiary	-	(1,440,000)
Investments in subsidiaries	-	100,000
(Investments)/ Disposal of associates	-	-
Dividend received	-	-
Investments in Short Term Investments	-	-
Disposal of Subsidiary (net of cash)	-	-
Proceeds on disposal of shares held in subsidiary	-	-
(Investments)/ Disposal in Short term Investments	(588,359)	(25,000)
Acquisition of property, plant & equipment	(1,791)	(1,332)
<b>Net cash used in investing activities</b>	<b>(446,243)</b>	<b>(1,299,180)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Receipts of interest bearing borrowings	-	771,000
Repayment of interest bearing borrowings	-	(771,000)
Payment of lease liabilities	(15,543)	(19,860)
Dividend paid	(1,057,744)	(245,987)
<b>Net Cash generated from / (used in) Financing Activities</b>	<b>(1,073,287)</b>	<b>(265,847)</b>
Net increase/(decrease) in cash and cash equivalents	(97,212)	(394,270)
Cash and cash equivalents at the beginning of the period	814,025	1,208,295
<b>Cash and cash equivalents at the end of the period</b>	<b>716,813</b>	<b>814,025</b>
<b>Cash and cash equivalents</b>		
Cash in hand & bank	716,813	814,025
Bank overdraft	-	-
	<b>716,813</b>	<b>814,025</b>

Figures in brackets indicate deductions.  
The above figures are not audited

## SEGMENTAL ANALYSIS

FOR THE PERIOD ENDED 31 ST DECEMBER 2023

	Investment and Management Services		Healthcare		Agri		Consumer Goods		Rental business		Intragroup		Group	
	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Revenue	3,155,937	2,973,961	21,036,604	17,640,105	6,483,336	6,649,162	14,832,031	14,090,038	19,266	29,393	(3,141,456)	(2,821,264)	42,385,719	38,561,395
<b>RESULT</b>														
Profit from operating activities	3,038,850	2,859,612	3,403,390	2,088,490	2,323,592	2,756,905	1,780,453	904,643	14,823	26,109	(3,167,394)	(2,813,839)	7,393,714	5,821,921
Net finance cost	137,934	36,292	(202,888)	(435,143)	64,583	21,611	(270,134)	(221,341)	(12,540)	(28,239)	-	-	(283,044)	(626,820)
Share of equity accounted investee	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of Goodwill	-	-	-	(150,000)	-	(60,000)	-	-	-	-	-	-	-	(210,000)
Income tax expense	735	(176,251)	(1,020,401)	(678,058)	(184,879)	(124,006)	(455,982)	(185,510)	(1,049)	(42,637)	-	-	(1,661,576)	(1,206,462)
<b>Profit for the year</b>	<b>3,177,519</b>	<b>2,719,653</b>	<b>2,180,101</b>	<b>825,289</b>	<b>2,203,296</b>	<b>2,594,510</b>	<b>1,054,337</b>	<b>497,792</b>	<b>1,234</b>	<b>(44,767)</b>	<b>(3,167,394)</b>	<b>(2,813,839)</b>	<b>5,449,092</b>	<b>3,778,639</b>
<b>Discontinued operations</b>														
Other comprehensive income	-	-	-	-	-	-	(1,125)	2,576	-	-	-	-	(1,125)	2,576
<b>Total comprehensive income</b>	<b>3,177,519</b>	<b>2,719,653</b>	<b>2,180,101</b>	<b>825,289</b>	<b>2,203,296</b>	<b>2,594,510</b>	<b>1,053,211</b>	<b>500,368</b>	<b>1,234</b>	<b>(44,767)</b>	<b>(3,167,394)</b>	<b>(2,813,839)</b>	<b>5,447,967</b>	<b>3,781,215</b>

## OTHER INFORMATION

	Investment and Management Services		Healthcare		Agri		Consumer Goods		Rental business		Intragroup		Group	
	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000
	31st December 2023	31st March 2023	31st December 2023	31st March 2023	31st December 2023	31st March 2023	31st December 2023	31st March 2023	31st December 2023	31st March 2023	31st December 2023	31st March 2023	31st December 2023	31st March 2023
Segment assets	13,342,469	12,979,903	20,358,597	14,809,533	8,884,577	8,865,548	9,265,767	8,570,907	1,253,039	1,247,623	(10,559,129)	(10,465,436)	42,545,321	36,008,081
Equity & reserves	13,122,685	12,602,911	8,619,203	6,995,726	6,266,581	6,502,988	3,331,431	2,491,431	846,873	845,639	(10,242,226)	(10,201,586)	21,944,547	19,237,110
Total liabilities	219,784	376,992	11,739,394	7,813,807	2,617,996	2,362,560	5,934,336	6,079,476	406,166	401,984	(316,903)	(263,850)	20,600,775	16,770,971
	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000	RS '000
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Depreciation	21,907	24,126	242,727	267,129	291,133	338,270	112,844	173,342	-	-	-	-	668,611	802,867
Capital expenditure	1,732	39,138	362,963	300,811	607,492	738,071	148,862	576,080	-	-	-	-	1,121,049	1,654,100

Figures in brackets indicate deductions.  
The above figures are not audited

## NOTES TO THE ACCOUNTS

### 1. Corporate information

Sunshine Holdings PLC (the "Company") is a Company incorporated and domiciled in Sri Lanka. The ordinary shares of the Company are listed on Colombo Stock Exchange of Sri Lanka. The address of the Company's registered office is no. 60, Dharmapala Mawatha, Colombo 03, Sri Lanka.

The Group is primarily involved in managing portfolio of investments which includes manufacturing, importing and selling of pharmaceuticals & medical devices, selling and export of branded tea, manufacturing of confectionery, fresh milk, palm oil and related products.

### 2. Interim condensed financial statements

"The Interim Condensed Financial Statements for the period ended 31 December 2023, includes the "Company" referring to Sunshine Holdings PLC as the holding Company and the "Group" comprise the Company and subsidiary companies of Sunshine Consumer Lanka Limited and its subsidiaries, Sunshine Healthcare Lanka Limited (SHL) and its subsidiaries, Sunshine Packaging Lanka Limited and its subsidiary, Sunshine Wilmar (Pvt) Ltd and its subsidiaries, Sunshine Tea (Pvt) Ltd and its subsidiaries.

The ultimate parent of the company is Lamurep Investments Limited which holds 55.18% of the issued share capital of the company as at 31st December 2023."

### 3. Approval of financial statements

The Interim Condensed Financial Statements of the Group and the Company for the period ended 31 December 2023, were authorised for issue by the Board of Directors on 13 February 2024.

### 4. Basis of preparation

"The Interim Condensed Consolidated Financial Statements have been prepared in accordance with the Sri Lanka Accounting Standards with effect from 01 January 2014 (SLFRS/LKAS). There were no changes to the accounting policies and methods of computation since the publication of the Annual Report 2022/23. Further, these Financial Statements have been prepared in compliance with the requirement of the Sri Lanka Accounting Standard - LKAS 34 on "Interim Financial Reporting"

The Interim Condensed Consolidated Financial Statements do not include all the information and disclosures required in the Annual Financial Statements, and should be read in conjunction with the Group's annual Consolidated Financial Statements as at 31 March 2023.

### 5. Significant Accounting Policies

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 March 2023.

#### 5.1. Standards Issued but not yet Effective

A number of new standards and amendments to standards are effective for annual periods beginning after 1 April 2023 and early application is permitted; however the Group has not early adopted any of the forthcoming new or amended standards in preparing these condensed consolidated interim financial statements.

#### 5.2. Basis of Consolidation

Subsidiaries are those entities controlled by the Group. Control is the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, the Group takes in to consideration that substantive rights that give the ability to direct the activities of the subsidiaries.

The Financial Statements of the subsidiaries are included in the Consolidated Financial Statements from the date the control effectively commences until the date that control effectively ceases. Non- controlling interest is measured at the proportionate share of the acquiree's identifiable net assets. A change in the

ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

#### 5.3. Use of judgements and estimates

In preparing these interim condensed financial statements, management has made judgements and estimates that affected the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ these estimates.

The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

#### 5.4. Property, Plant & equipment

##### Recognition and measurement

Property, plant and equipment is recorded at cost less accumulated depreciation and accumulated impairment losses if any, whilst land is measured at fair value.

##### De-recognition

The carrying amount of an item of Property, plant & equipment is de-recognised on disposal; or when no future economic benefits are expected from its use. Gains and losses on de-recognition are recognised in income statement and gains are not classified as revenue. When re-valued assets are sold, any related amount included in the revaluation reserve is transferred to Retained Earnings.

##### Depreciation

Depreciation is recognised in income statement on a straight-line basis over the estimated useful lives of each part of an item of property, plant & equipment.

##### 5.4.1 Impairment

The Board of Directors has assessed the potential impairment loss of the property, plant and equipment as at 31 March 2023. Based on the assessment, no impairment provision is required to be made in the financial statements as at the reporting date.

#### 5.5. Biological assets

The Group recognise the biological assets when, and only when, the Company controls the assets as a result of past events, it is probable that future economic benefits associated with the assets will flow to the entity and fair value or cost of the assets can be measured reliably.

##### Bearer biological assets

Tea, rubber, oil palm, cinnamon, sundry crops and nurseries are classified as bearer biological assets. The bearer biological assets are measured at cost less accumulated depreciation and accumulated impairment losses, if any, in terms of Sri Lanka Accounting Standard LKAS 16 - Property Plant and Equipment as per the ruling issued by Institute of Chartered Accountants of Sri Lanka.

##### Consumable biological assets

Timber plantation is classified as consumable biological assets and is measured on initial recognition and at the end of each reporting period at fair value less cost to sell. Costs to sell include all costs that would be necessary to sell the assets, including transportation costs. The fair value of trees younger than five years cannot be reliably estimated and are carried at cost less impairment. The cost includes direct material, direct labour and appropriate proportion of directly attributable overheads. Gains or losses arising on initial recognition of timber plantations at fair values less costs to sell and from the change in fair values less costs of plantations at each reporting date are included in profit or loss for the period in which they arise. All costs incurred in maintaining the assets are included in Profit or Loss for the period in which they arise.

##### Livestock

Livestock is measured at their fair value less estimated point of sale costs. Changes in fair value of livestock are recognised in the income statement.

## NOTES TO THE ACCOUNTS (Cont...)

### 5.6. Investment properties

Investment properties are measured initially at cost, including transaction costs. The carrying value of an investment property includes the cost of replacing part of an existing investment property, at the time that cost is incurred if the recognition criteria are met, and excludes the costs of day-to-day servicing of the investment property. Subsequent to initial recognition, the investment properties are stated at fair values, which reflect market conditions at the reporting date. Gains or losses arising from changes in fair value are included in the income statement in the year in which they arise. Fair values are evaluated at least every 3 years by an accredited external, independent valuer. Investment properties are derecognised when disposed, or permanently withdrawn from use because no future economic benefits are expected. Any gains or losses on retirement or disposal are recognised in the income statement in the year of retirement or disposal.

### 5.7 Inventories

Inventories other than produce stock and nurseries are stated at the lower of cost or net realisable value, after making due allowances for obsolete and slow moving items. The Group uses weighted average cost formula and actual cost in assigning the cost of inventories. The cost includes expenses in acquiring stocks, production and conversion cost and other costs incurred in bringing them to their existing location and condition.

### 6. Revenue

Revenue recognition under SLFRS 15 is based on the nature and timing of satisfaction of performance obligations, including significant payment terms.

SLFRS 15 - Revenue from contracts with customers, establishes a comprehensive framework for determining whether, how much and when revenue is recognised. The Group recognises revenue when a customer obtains control of the goods or services. Judgement is used to determine the timing of transfer of control - at a point in time or over the time.

#### a) Investments

Dividend income is recognised in profit or loss on the date on which the company or its subsidiaries right to receive payment is established. This is now under the scope of SLFRS 9.

#### b) Plantation

Customers obtain the control of the produce after the customer acknowledgement at the dispatch point. Revenue is recognized point in time, at the time of dispatch after the customer acknowledgement.

#### c) Consumer

Customers obtain control of the goods sold when the goods are delivered to and have been accepted at their premises. Invoices are generated at that point in time. Revenue is recognized when a customer obtains control of the goods or services. Determining the timing of the transfer of control is at a point in time.

#### d) Healthcare

Customers obtain control of the goods sold when the goods are delivered to and have been accepted at their premises. Invoices are generated at that point in time. Revenue is recognized when a customer obtains control of the goods or services. Determining the timing of the transfer of control is at a point in time.

#### e) Sunshine Tea

This includes income of tea export to different countries. Revenue is recognised point in time, at the time of dispatch after the customer acknowledgement.

#### f) Rent income

This includes rental income earned from renting out investment property owned by the Subsidiary. Revenue is recognized over time as the rent income is

recognized on a straight line basis over the term of the agreement.

### 6.1 Disaggregation of Revenue from Contracts with Customers

The disaggregation of revenue has been provided under segmental analysis.

### 7. Investments in subsidiaries

Quoted and unquoted investments in shares held on long term basis by the Company and Group are stated at cost less provision for diminution in value of investments.

#### 7.1. Change In NCI

Akbar Pharmaceutical Holdings (Private) Limited was amalgamated with Lina Manufacturing (Pvt) Ltd with effect from 16 March 2023. Accordingly, on the 16 March 2023 the book value of Akbar Pharmaceutical Holdings (Private) Limited was amalgamated with Lina Manufacturing (Pvt) Ltd and Akbar Pharmaceutical Holdings (Private) Limited company name has been discontinued with all operations being transacted under the name of Lina Manufacturing (Pvt) Limited.

On August 03, 2023, Lina Manufacturing Private Limited ("LMPL"), which is a subsidiary of Sunshine Healthcare Lanka Limited, became a 100% ownership of Lina Spiro (Private) Limited ("LSPL") with the acquisition of remaining Non-Controlling Interest of 49%. The consideration for this purchase was satisfied by the issuance of new ordinary (voting – removed) shares in Lina Manufacturing (Pvt) Ltd to Celogen for a consideration of Rs.307 million. As a result of this transaction, the effective shareholding in LMPL held by the SHL diluted from 90.62% to 71.6%.

Gordon Frazer & Bosanquate Skrine company Ltd was amalgamated with Sunshine Tea (Pvt) Ltd a fully owned subsidiary of Sunshine Tea (Pvt) Ltd with effect from 27 September 2023. Accordingly, the book value of Gordon Frazer & Bosanquate Skrine company Ltd was amalgamated with Sunshine Tea (Pvt) Ltd and Sunshine Tea (Pvt) Ltd continues as the surviving entity.

#### 7.2. Investment in a Subsidiary

The Company has entered into a share sale and purchase agreement with Mr Govindasamy Sathasivam, the owner of Sunshine Tea (Private) Limited ("STPL"), whereby the Company acquired Three Million Five Hundred Thousand (3,500,000) shares which amounts to 100% of the total issued shares of STPL, at a total consideration of Sri Lanka Rupees One Billion Four Hundred and Forty Million (Rs.1,440,000,000) on 1 April 2022.

The board of directors of SUN at the meeting held on 18 January 2024 resolved to infuse a sum of Sri Lanka Rupees Five Hundred Million (Rs. 500,000,000/-) into the capital of its subsidiary STPL. STPL will accordingly capitalize such sum of Sri Lanka Rupees Five Hundred Million (Rs. 500,000,000/-) by the issue of fully paid ordinary shares to the Company.

## NOTES TO THE ACCOUNTS (Cont...)

### 8. Valuation of Financial Assets and Liabilities

#### 8.1. Accounting Classification and Fair Values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

31st December 2023	Classification	GROUP					COMPANY				
		Carrying amount	Fair value			Total	Carrying amount	Fair value			Total
			Level 1	Level 2	Level 3			Level 1	Level 2	Level 3	
<b>Financial Assets measured at Fair value</b>											
Investment in Unquoted Shares	Fair value through OCI	309,911	-	-	309,911	309,911	-	-	309,911	-	309,911
Investment in Quoted Shares	Fair value through P&L	27,219	27,219	-	-	27,219	27,219	-	-	-	27,219
Investment Fund	Fair value through P&L	45,048	-	45,048	-	45,048	-	-	-	-	-
		<b>382,178</b>	<b>27,219</b>	<b>45,048</b>	<b>309,911</b>	<b>382,178</b>	<b>337,130</b>	<b>27,219</b>	<b>-</b>	<b>309,911</b>	<b>337,130</b>
<b>Financial Assets not measured at Fair value</b>											
Trade and other receivables **	Amortized cost	11,679,113	-	11,679,113	-	11,679,113	59,599	-	59,599	-	59,599
Investment in Debentures	Amortized cost	101,239	-	101,239	-	101,239	101,239	-	101,239	-	101,239
Amounts due from related parties **	Amortized cost	97,625	-	97,625	-	97,625	278,063	-	278,063	-	278,063
Cash & cash equivalents **	Amortized cost	3,733,529	-	3,733,529	-	3,733,529	716,813	-	716,813	-	716,813
		<b>15,611,505</b>	<b>-</b>	<b>15,611,505</b>	<b>-</b>	<b>15,611,505</b>	<b>1,155,713</b>	<b>-</b>	<b>1,155,713</b>	<b>-</b>	<b>1,155,713</b>
<b>Financial Liabilities not measured at Fair value</b>											
Loans and borrowings ***	Other financial liabilities	6,382,915	-	6,382,915	-	6,382,915	5,137	-	5,137	-	5,137
Bank overdraft **	Other financial liabilities	2,800,071	-	2,800,071	-	2,800,071	-	-	-	-	-
Trade and other payables **	Other financial liabilities	8,213,228	-	8,213,228	-	8,213,228	59,468	-	59,468	-	59,468
Amounts due to related parties **	Other financial liabilities	-	-	-	-	-	-	-	-	-	-
		<b>17,396,214</b>	<b>-</b>	<b>17,396,214</b>	<b>-</b>	<b>17,396,214</b>	<b>64,605</b>	<b>-</b>	<b>64,605</b>	<b>-</b>	<b>64,605</b>

31 March 2023	Classification	GROUP					COMPANY				
		Carrying amount	Fair value			Total	Carrying amount	Fair value			Total
			Level 1	Level 2	Level 3			Level 1	Level 2	Level 3	
<b>Financial Assets measured at Fair value</b>											
Investment in Unquoted Shares	Fair value through OCI	309,911	-	-	309,911	309,911	-	-	309,911	-	309,911
Investment in Quoted Shares	Fair value through P&L	21,011	21,011	-	-	21,011	21,011	21,011	-	-	21,011
Investment Fund	Fair value through P&L	53,283	-	53,283	-	53,283	-	-	-	-	-
		<b>384,205</b>	<b>21,011</b>	<b>53,283</b>	<b>309,911</b>	<b>384,205</b>	<b>330,922</b>	<b>21,011</b>	<b>-</b>	<b>309,911</b>	<b>330,922</b>
<b>Financial Assets not measured at Fair value</b>											
Trade and other receivables **	Amortized cost	7,892,295	-	7,892,295	-	7,892,295	28,133	-	28,133	-	28,133
Investment in Debentures	Amortized cost	104,173	-	104,173	-	104,173	104,173	-	104,173	-	104,173
Short term investment	Amortized cost	-	-	-	-	-	-	-	-	-	-
Amounts due from related parties **	Amortized cost	149,443	-	149,443	-	149,443	233,869	-	233,869	-	233,869
Cash & cash equivalents **	Amortized cost	3,110,102	-	3,110,102	-	3,110,102	814,025	-	814,025	-	814,025
		<b>11,256,013</b>	<b>-</b>	<b>11,256,013</b>	<b>-</b>	<b>11,256,013</b>	<b>1,180,200</b>	<b>-</b>	<b>1,180,200</b>	<b>-</b>	<b>1,180,200</b>
<b>Financial Liabilities not measured at Fair value</b>											
Loans and borrowings ***	Other financial liabilities	5,298,977	-	5,298,977	-	5,298,977	19,776	-	19,776	-	19,776
Bank overdraft **	Other financial liabilities	2,108,469	-	2,108,469	-	2,108,469	-	-	-	-	-
Trade and other payables **	Other financial liabilities	6,423,945	-	6,423,945	-	6,423,945	34,158	-	34,158	-	34,158
Amounts due to related parties **	Other financial liabilities	55,000	-	55,000	-	55,000	12	-	12	-	12
		<b>13,886,391</b>	<b>-</b>	<b>13,886,391</b>	<b>-</b>	<b>13,886,391</b>	<b>53,946</b>	<b>-</b>	<b>53,946</b>	<b>-</b>	<b>53,946</b>

\*\* Classes of financial instruments that are not carried at fair value and of which carrying amounts are a reasonable approximation of fair value. This includes trade receivables, cash and cash equivalents, trade payable, other payables, amounts due to and due from related parties and bank overdraft. The carrying amounts of these financial assets and liabilities are a reasonable approximation of fair values due to their short term nature.

\*\*\* Discounted cash flows: The valuation model considers the present value of expected payments, discounted using a risk-adjusted discount rate.

#### 8.2. Measurement of Fair Values

##### Financial Assets and Liabilities measured or disclosed at Fair Value

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The Company and Group measures the fair value using the following fair value hierarchy, which reflects the significance of the inputs used in making the measurement.

## NOTES TO THE ACCOUNTS (Cont...)

An analysis of the fair value measurement of financial and non-financial assets and liabilities are provided below:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

When available, the Company and Group measures the fair value of an instrument using active quoted prices or dealer price quotations (assets and long positions are measured at a bid price; liabilities and short positions are measured at an ask price), without any deduction for transaction costs. A market is regarded as active if transactions for assets or liabilities take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

This category includes instruments valued using:

- (a) quoted prices in active markets for similar instruments,
- (b) quoted prices for identical or similar instruments in markets that are considered to be less active, or
- (c) other valuation techniques in which almost all significant inputs are directly or indirectly observable from market data.

- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs). This category includes all instruments for which the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instrument's valuation.

### 8.2.a Valuation techniques and significant unobservable inputs

The following valuation techniques used in measuring Level 2 and Level 3 fair values at 31 December 2023 and 31 March 2023 for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used.

#### • Unquoted equity instruments - Discounted cash flows

The valuation model considers A85:N93 present value of expected net cash flows from those investments discounted using a risk adjusted discount rate. The expected cash flows are derived based on the budgeted cash flow forecasts of those investments determined by considering the sensible probability of the forecast EBITDA.

#### • Interest rate swaps/Cross currency swaps- Swap models

The fair value is calculated as the present value of the estimated future cash flows. Estimates of future floating-rate cash flows are based on quoted swap rates, futures prices and interbank borrowing rates. Estimated cash flows are discounted using a yield curve constructed from similar sources and which reflects the relevant benchmark interbank rate used by market participants for this purpose when pricing interest rate swaps. The fair value estimate is subject to a credit risk adjustment that reflects the credit risk of the Group and of the counterparty; this is calculated based on credit spreads derived from current credit default swap or bond prices.

Those assumptions for assets categorised as Level 3 has been described under respective notes to the financial Statements as at 31 March 2023.

During the reporting period ended 31 December 2023 and 31 March 2023, there were no transfers between Level 1 and Level 2 fair value measurements.

### 8.3. Concentration on Credit Risk

The Group's concentration on Credit Risk as at 31 December 2023 remain the same as at 31 March 2023.

## 9. Comparatives

The presentation and classification of the Financial Statements of the previous periods have been amended, where relevant, for better presentation and to be comparable with those of the current period.

## 10. Stated capital is represented by shares in issue as given below:

No. of shares as at	31 December 2023	31st March 2023
Ordinary shares	491,973,629	491,973,629

## 11. Dividend

	Period ended 31st December 2023	Period ended 31st December 2023	Period ended 31st March 2023
	2023/24 (Interim) RS '000	2022/23 (Final) RS '000	2021/22 (Interim) RS '000
Dividend paid (Rs)	491,974	565,770	245,987
No of ordinary shares	491,974	491,974	491,974
Dividend per share (cash)	1.00	1.15	0.50

## 12. Commitments & contingencies

There has not been significant change in the nature of the contingent liabilities, which were disclosed in the Annual Report for the year ended 31st March 2023.

## 13. Income tax

Tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in Statement of Profit or Loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income.

The Group has determined that interest and penalties relating to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under LKAS 37 Provisions, Contingent Liabilities and Contingent Assets.

## 14. Earnings per share

The earnings per share is computed on the profit attributable to ordinary shareholders after tax and non-controlling interest divided by the weighted average number of ordinary shares during the period. Further there was no dilution of ordinary shares outstanding at any time during the period. Therefore, diluted earnings per share is the same as basic earning per share.

## 15. Net Assets per share

Net assets per share has been calculated, for all periods, based on the number of shares issued as at the reporting date.

## 16. The interim Financial Statements are not audited.

## SHAREHOLDER INFORMATION

Market price per share	Period ended	Audited
	31 December	Year ended
	2023	31st March 2023
	Rs.	Rs.
Highest price	54.80	46.50
Lowest price	44.00	34.00
Last traded price	51.00	45.00

### TWENTY (20) LARGEST SHAREHOLDERS AS AT

S/N Name	31 December 2023		31st March 2023	
	No of Shares Held	%	No of Shares Held	%
1 Lamurep Investments Limited Account No.04 & 01	271,454,139	55.18%	271,454,139	55.18%
2 Akbar Brothers Pvt Ltd A/C No 1	49,241,855	10.01%	49,241,855	10.01%
3 Deepcar Limited	45,774,076	9.30%	45,574,076	9.26%
4 Citibank Newyork S/A Norges Bank Account 2	14,142,347	2.87%	6,971,908	1.42%
5 Ceylon Property Development Limited	10,915,876	2.22%	10,915,876	2.22%
6 Thread Capital (Private) Limited	8,689,483	1.77%	6,167,304	1.25%
7 Mr.V.Govindasamy	6,079,500	1.24%	6,079,500	1.24%
8 Invenco Capital Private Limited	3,274,336	0.67%	-	0.00%
9 MR. B.W.Kundanmal	3,223,728	0.66%	2,745,922	0.56%
10 Rubber Investment Trust Ltd A/C No 01	3,097,338	0.63%	2,097,307	0.43%
11 Union Assurance PLC - Universal Life Fund	2,878,273	0.59%	1,481,161	0.30%
12 Perera And Sons Bakers Pvt Limited	2,500,000	0.51%	1,500,000	0.30%
13 Ceylon Guardian Investment Trust PLC A/C # 02	2,494,277	0.51%	1,494,277	0.30%
14 Deutsche Bank Ag As Trustee To Assetline Income Plus Growth Fund	2,000,000	0.41%	-	0.00%
15 Deutsche Bank Ag As Trustee for JB Vantage value equity fund	1,830,238	0.37%	-	0.00%
16 Ceylon Investment PLC A/C # 02	1,630,000	0.33%	-	0.00%
17 J.B.Cocoshell (PVT) Limited	1,512,369	0.31%	-	0.00%
18 Employees Trust Fund	1,329,566	0.27%	-	0.00%
19 Union Assurance PLC - Universal Life Fund	1,217,077	0.25%	1,481,161	0.30%
20 Bank Of Ceylon No.1 Account	1,196,198	0.24%	949,010	0.19%
Sub Total	434,480,676	88.31%	408,153,496	82.96%
Others	57,492,953	11.69%	83,820,133	17.04%
<b>Total</b>	<b>491,973,629</b>	<b>100.00%</b>	<b>491,973,629</b>	<b>100.00%</b>

### PUBLIC SHARE HOLDING

	Requirement by CSE	As at 31st December 2023	Requirement by CSE	As at 31st March 2023
Option	3	3	3	3
Float adjusted market capitalization	Above Rs.5,000,000,000/-	7,865,920,367	Above Rs.5,000,000,000/-	6,940,517,971
The percentage of shares held by the public	7.5%	31.35%	7.5%	31.35%
Number of shareholders representing public holding	500	6,088	500	7,369

The number of shares held by the Board of Directors are as follows:

	As at 31st December 2023	As at 31st March 2023
Mr.V. Govindasamy -(Deputy Chairman w.e.f. 25th January 2024)	6,079,500	6,079,500
Mr.G.Sathasivam	9,165	9,165
Mr. S.G. Sathasivam- (Group Chief Executive Officer w.e.f. 25th January 2024)	3,054	3,054
Mr.A.D.B.Talwate	3,054	3,054



## CORPORATE INFORMATION

### Name of Company

Sunshine Holdings PLC

### Legal Form

Public Limited Liability Company  
(Incorporated in 1973 and listed in the Colombo Stock Exchange)

### Company Registration Number

PQ13

### Principal Activities

Holding Company, carrying out investment in subsidiaries

### Registered Office

No. 60, Dharmapala Mawatha, Colombo 03

### Directors

Mr. D. A. Cabraal  
Mr. V. Govindasamy - (Deputy Chairman w.e.f. 25th January 2024)  
Mr. S. G. Sathasivam - (Group Chief Executive Officer w.e.f. 25th January 2024)  
Mr. A. Talwatte  
Mr. G. Sathasivam  
Mr. S. Shishoo  
Mr. Sudarshan Jain  
Mr. S. Renganathan  
Mr. Tyeabally Akbarally  
Mr. Reyaz Mihular - Appointed w.e.f. 06th April 2023  
Ms. Aruni Goonetilleke - Appointed w.e.f. 15th November 2023  
Mr. Aruna Deepthikumara - Appointed w.e.f. 18th January 2024  
Mr. Harsha Abeywickrama - Resigned from 24th May, 2023  
Ms. W. Y. R. Fernando - Resigned from 27th October, 2023

### Secretaries

Corporate Services (Private) Limited  
No. 216, De Seram Place,  
Colombo 10  
Tel: 011 4 605 100

### Auditors

KPMG  
Chartered Accountants  
32A, Sri Mohamed Macan Marker Mawatha,  
Colombo 03

### Lawyers

F J & G de Saram (Attorney-at-Law)  
No. 216, de Saram Place  
Colombo 10

Nithya Partners  
Attorneys-at-Law  
No. 97/A, Galle Road  
Colombo 03

### Bankers

Hatton National Bank PLC  
National Development Bank PLC  
MCB Bank Limited  
Standard Chartered Bank Ltd.  
Seylan Bank PLC  
Nations Trust Bank PLC  
Commercial Bank PLC  
Indian Overseas Bank  
Hongkong and Shanghai Banking Corporation Limited  
DFCC Bank PLC  
Indian Bank

### Credit Ratings

The Company has been assigned a national long-term rating of 'AA+(lka)'; outlook stable by Fitch Ratings Lanka Limited